Metastatic Breast Cancer Network

05/29/2021

Take an anonymous survey for MBC patients. Share your thoughts about clinical trials to help make life-saving research more diverse, and easier to access.

05/11/2021

Give input & connect to clinical trials through a patient-powered registry.

05/06/2021

The FDA granted accelerated approval to pembrolizumab (Keytruda) in combination with trastuzumab (Herceptin) and chemotherapy as initial treatment for unresectable or metastatic HER2-positive gastric or gastroesophageal junction cancer.

More than two thirds of patients with HER2-positive breast cancer and brain metastases benefited from pertuzumab (Perjeta) plus high-dose trastuzumab, including two patients whose brain lesions remained stable for more than 2 years. (Journal of Clinical Oncology)

source: https://www.medpagetoday.com/hematologyoncology/othercancers/92458?xid=nl_mpt_SROncology_2021-05-06&eun=g1459386d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=OncoUpdate_050621&utm_term=NL_Spec_Oncology_Update_Activehttps://www.medpagetoday.com/hematologyoncology/othercancers/92458?xid=nl_mpt_SROncology_2021-05-06&eun=g1459386d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=OncoUpdate_050621&utm_term=NL_Spec_Oncology_Update_Active

05/06/2021

Behind the scenes with bone boosters...

There's a growing interest in the use of bone-modifying agents, or BMAs, known as bisphosphonates in the cancer patient population. But these agents can cause short- and long-term side effects. What’s the story with BMAs in breast cancer? We chatted with patients, cancer researchers, and clinician...

05/05/2021

“The treatment of HER2+ metastatic breast cancer is 1 of the success stories in oncology....”

Adam M. Brufsky, MD, PhD: Welcome to this Cancer Network® presentation “Around the Practice: Relapsed/Refractory HER2+ Metastatic Breast Cancer.”

05/05/2021

Relapsed/Refractory HER2+ Metastatic Breast Cancer - Episode 1

Best Practices: HER2+ MBC With Brain Mets

Adam M. Brufsky, MD, PhD: Let’s do a polling question for the audience. What factors are important when deciding whether to continue current systemic therapy vs switching or recommending local therapy for a patient who develops CNS [central nervous system] progression after starting frontline ther...

05/04/2021

Join Kelly Shanahanand Dr Ben Ho Park Tues 5/4 9 Pacific (10 min, 11 central, noon eastern) to honor the legacy of super advocate Sandi Spivey.

Register here: https://www.eventbrite.com/e/ais-coffee-chat-tickets-151858776689?fbclid=IwAR3DJPl-mBvjvrvr2b8p6c-jM9zkBhUhNpPjhrAl5SaYls3QgIGorfSrslw

Coffee Chats with Advocates and Researchers are casual conversations where advocates can connect directly with researchers and ask questions

05/03/2021

Share your experiences during the pandemic to help doctors provide better care. Together we can drive advances in metastatic breast cancer treatment & research.

Help us reach 500 survey responses: https://mbca.me/3tijm5N

04/27/2021

COMING SOON! Take two surveys about your experience during the pandemic to help doctors provide better care. Your voice can make a difference for metastatic breast cancer.

Join this patient-powered registry today: https://mbca.me/3tijm5N

04/23/2021

04/22/2021

Many people, and even doctors, are not familiar with the term oligometastatic breast cancer. Oligometastatic breast cancer is characterized by single or few detectable metastatic lesions at the time of diagnosis. People with oligomets may have improved outcomes and may even experience treatment as curative. In this interview, Debu Tripathy, MD, explains this relatively rare presentation of MBC, explores treatment approaches, and shares a look into the research.

Many people, and even doctors, are not familiar with the term oligometastatic breast cancer. Oligometastatic breast cancer is characterized by single or few ...

04/18/2021

Casting for Recovery offers free retreats for all people with all stages of breast cancer. Learn more...

Casting for Recovery focuses on enhancing the quality of life of women with breast cancer through a unique program that combines breast cancer education...